HIV & AIDS

New high-cost HIV prevention drug: 'Better' isn't worth it

A newly approved drug for HIV pre-exposure prophylaxis (PrEP) is unlikely to confer any discernible health benefit over generic alternatives and may undermine efforts to expand access to HIV prevention for the nation's most ...

Diabetes

Treating oral disease could yield T2DM-related cost savings

(HealthDay)—Providing nonsurgical periodontal treatment to patients with type 2 diabetes (T2D) and periodontitis may significantly reduce tooth loss and diabetes-related microvascular diseases via improved glycemic control, ...

page 11 from 19